reports
Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Confe...
Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Thursday, August 8, 2019, the Company will report financial results for its fiscal 2019 third quarter ended June 30, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. ...
Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion ...
Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment MIAMI, July 18, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced the dismissal of litigation against the Company and certain of its officers and directors. In response to the Company’s acquisition of Aspen Park Pharmaceuticals, Inc., two purported derivative and class action lawsuits were filed against the Company and certain of its office...
Veru Announces Successful Completion of Pre-NDA Meeting with FDA for T...
Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia --Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway—-- TADFIN is a First Novel Combination Formulation of Tadalafil and Finasteride for the Treatment of BPH with NDA Submission Anticipated in Summer of 2020-- MIAMI, June 26, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medi...
Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation ...
Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA — VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical Development Strategy — MIAMI, June 04, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel me...
Veru to Present at the Jefferies 2019 Global Healthcare Conference on ...
Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th MIAMI, May 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 2:00 p.m. ET at the Grand Hyatt New York hotel. A webcast of the presentation will be available at . The webcast will be archived and accessible on the web site for at least 90 d...
Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results
Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results -- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –-- Strong Financial Results for Q2 and YTD FY 2019 ---- Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET – MIAMI, May 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU) an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced its financial results for its fiscal 2019 second quarter ended March 3...
Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conf...
Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Wednesday, May 15, 2019, the Company will report financial results for its fiscal 2019 second quarter ended March 31, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. E...
Veru to Participate in Two Investor Conferences in March
Veru to Participate in Two Investor Conferences in March MIAMI, March 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced its participation in two upcoming investor conferences. Schedule as follows: Barclays Global Healthcare Conference on March 12–14, 2019 at the Loews Miami Beach Hotel. Veru will meet with investors. There will be no webcast.Oppenheimer 29th Annual Healthcare Conference. Veru will present at...
Veru Reports Strong Fiscal 2019 First Quarter Financial Results
Veru Reports Strong Fiscal 2019 First Quarter Financial Results -- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET -- MIAMI, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today reported financial results and business highlights for its fiscal...
Veru Announces Scientific Presentations for Novel Prostate Cancer Drug...
Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that four presentations relating to Veru drug candidates are being given at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium being held February 14-16, 2...
Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Confe...
Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that on Wednesday, February 13, 2019, the Company will report financial results for its fiscal 2019 first quarter ended December 31, 2018, before the market opens. Veru’s management will host a conference call that same day at 8 am Eastern Time to review ...
Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class D...
Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer --Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End-- -- Drug Addresses Significant Unmet Medical Need -- MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a clinical trial of its proprietary, next generation prostate cancer drug, VERU-111. The open-label Phase 1b/2 clinical trial for VERU-111, a novel oral drug, will be e...
Veru Announces Acceptance of Four Abstracts for Presentation at the Ge...
Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019 MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held February 14-16, 2019, at the Moscone West Building in San Francisco, California. Three of the presentations will be for VERU-111, the Company’s proprietary, next generatio...
Veru Announces Successful Bioavailability and Bioequivalence Clinical ...
Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia Company Plans to Submit NDA in 2019 MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and Finasteride Combination tablet met the U.S. Food and Drug Administration’s (FDA) requirements for bioavailability and bioequivalence for the co-administration of tadalafil 5mg and finasteride 5mg do...
Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Four...
Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter -- Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes Stock Offering, Awarded Large FC2 Tender -- Company to Host Investor Conference Call on Thursday, December 13, 2018, 8 a.m. ET MIAMI, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU) today announced its financial results for the fiscal (FY) 2018 fourth-quarter and full-year ended September 30, 2018. “Our fiscal 2018 fourth...
Veru to Report Fiscal Year 2018 Financial Results, Host Conference Ca...
Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th MIAMI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on Thursday, December 13, 2018, the company will report financial results for the fourth quarter and fiscal year ended September 30, 2018, before the market opens. Veru management will host a conference call that same day at 8 a.m. Eastern Time to review the company’s performance and to answer questions. Event DetailsInterested investors may access the call by di...
Veru Announces First Patient Dosed in Bioequivalence Clinical Trial fo...
Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia -- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that the Company has dosed its first patient for its bioequivalence study of Tadalafil (Cialis®) and Finasteride (PROSCAR®) combination tablet for benign prostatic hyperplasia (BPH)...
Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refract...
Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer -- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for VERU-111 (bisindole), a first-in-class, next generation, proprietary, oral tubulin inhibitor for t...
First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Tr...
First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy MIAMI, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced the enrollment of the first patient in its Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by androgen deprivation therapy (ADT) for men with advanced prostate cancer. The double-blind, placebo-controlled, dose-finding study is designed to evaluate the safety and efficacy of daily oral zuclomiphene...
Veru to Present at Upcoming Healthcare Investor Conferences in New Yor...
Veru to Present at Upcoming Healthcare Investor Conferences in New York MIAMI, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the company’s Chairman, President and Chief Executive Officer, Dr. Mitchell Steiner, will present an overview of the company’s development programs at the following investor conferences. Presentation details: Event: Cantor Fitzgerald Global Healthcare Conference Date: Monday, Oct. 1, 2018 Time: 8:55 a.m. EDT Location: InterContinental New York Barclay Hotel ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.